Tesamorelin
Price range: $148.80 through $219.60
Tesamorelin - Visceral Fat Reduction & Growth Hormone Stimulation
Description
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate endogenous growth hormone secretion from the pituitary gland. This action elevates circulating IGF-1 levels and enhances cellular repair, metabolism, and tissue regeneration without direct hormonal supplementation.
Research demonstrates that Tesamorelin reduces visceral adipose tissue (VAT) while preserving lean muscle mass, making it a central focus in studies of metabolic optimization and body recomposition. It has also shown potential in improving lipid profiles, liver health, and glucose tolerance in both clinical and experimental settings.
Beyond metabolic applications, Tesamorelin supports collagen synthesis, tissue healing, and neuroprotection through the GH-IGF-1 axis, contributing to ongoing research in recovery, aging, and cognitive performance enhancement.
Formulated in a stabilized pre-mixed injection pen for SubQ administration, Tesamorelin ensures high bioavailability and precision dosing for experimental use in hormonal, metabolic, and regenerative studies.
Clinical Status:
Tesamorelin is an FDA-approved peptide for the treatment of HIV-associated lipodystrophy and is being studied for expanded applications in metabolic and anti-aging research.
Evidence type:
Human RCT ✔ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory ✔
Mechanism of Action
Tesamorelin binds to GHRH receptors (GHRHR) on pituitary somatotrophs, activating the Gαs protein-coupled adenylate cyclase-cAMP-PKA signaling pathway. This results in increased GH synthesis and pulsatile secretion. The subsequent rise in circulating GH stimulates hepatic production of IGF-1, which mediates downstream anabolic and lipolytic effects via the PI3K-Akt-mTOR and JAK-STAT pathways. Unlike exogenous GH, Tesamorelin preserves physiological feedback control, reducing desensitization risks and supporting sustained GH-axis activity. Its structural modification (addition of a trans-3-hexenoic acid group at the N-terminus) enhances resistance to DPP-IV degradation, extending its half-life for consistent biological activity.
Benefits
- Stimulation of Natural Growth Hormone Release:
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) studied for its ability to stimulate the pituitary gland to produce and release endogenous GH. This mechanism supports natural GH pulsatility and increases circulating IGF-1 levels, resulting in enhanced cellular repair, metabolism, and recovery functions observed in research models. - Reduction of Visceral and Abdominal Fat:
One of the most documented effects of Tesamorelin is its ability to reduce visceral adipose tissue (VAT) while preserving lean muscle mass. Clinical data show significant decreases in intra-abdominal fat, making it a leading peptide in studies exploring obesity, body recomposition, and metabolic optimization. - Improvement of Lipid and Metabolic Profiles:
Research has demonstrated that Tesamorelin improves lipid metabolism by lowering triglycerides and total cholesterol while enhancing HDL levels. These effects contribute to better cardiovascular health and metabolic balance, making it valuable in experimental models of dyslipidemia and cardiometabolic health. - Enhanced Muscle Regeneration and Recovery:
Tesamorelin indirectly promotes muscle growth and repair through IGF-1 activation, stimulating protein synthesis and satellite cell activity. This regenerative effect supports faster recovery after physical stress, injury, or intensive exercise, forming the basis of its use in muscle regeneration and rehabilitation research. - Improved Liver Health and Fat Metabolism:
Preclinical and clinical findings suggest Tesamorelin reduces hepatic steatosis and improves liver enzyme levels by modulating lipid metabolism and enhancing mitochondrial oxidation. These results have drawn interest in its potential role in non-alcoholic fatty liver disease (NAFLD) and liver regeneration studies. - Support for Cognitive and Neurological Function:
Emerging research shows Tesamorelin may have a positive impact on cognitive performance and memory through the neuroprotective effects of GH and IGF-1. These hormones enhance synaptic plasticity, neuronal survival, and glucose metabolism in the brain, supporting experimental exploration in neuroendocrine and cognitive health research. - Restoration of Natural Hormonal Rhythm:
Unlike exogenous GH, Tesamorelin preserves physiological growth hormone pulsatility, aligning with the body’s natural circadian rhythm. This balanced endocrine stimulation reduces the risk of receptor desensitization and provides a more natural restoration of hormonal homeostasis in long-term studies. - Enhancement of Collagen Synthesis and Skin Health:
Through IGF-1 pathway activation, Tesamorelin enhances collagen production and skin elasticity. These effects contribute to improved skin structure and wound repair, making it an area of interest in aesthetic and regenerative dermatology research. - Improvement in Physical Performance and Energy:
Research shows Tesamorelin increases mitochondrial efficiency and energy utilization, leading to improved stamina and physical capacity. Its anabolic and metabolic actions enhance muscle energy supply, making it suitable for studies examining endurance and performance recovery under metabolic stress. - Neuroprotective and Anti-Aging Implications:
GH and IGF-1 signaling activated by Tesamorelin has been observed to slow cellular aging processes by enhancing DNA repair, antioxidant activity, and protein turnover. These mechanisms contribute to its inclusion in experimental models of neuroprotection, metabolic longevity, and regenerative aging research. - FDA-Approved for Lipodystrophy Research Context:
Tesamorelin is FDA-approved for HIV-associated lipodystrophy, providing a well-documented safety and efficacy profile. Its research applications extend beyond this indication, including studies on metabolic syndrome, hormone restoration, and tissue repair through controlled GH axis modulation. - Synergistic Effects with CJC-1295 and Ipamorelin:
Combining Tesamorelin with CJC-1295 or Ipamorelin enhances growth hormone secretion frequency and amplitude. This synergistic protocol amplifies IGF-1 production, improving muscle recovery, fat metabolism, and energy output—making it a cornerstone combination in advanced GH secretagogue research.
Research Data
| Study/model | Reported effect |
| Human RCTs (HIV lipodystrophy) |
↓ Visceral fat by 15-20%, ↑ IGF-1 by 1.7-fold after 26 weeks
|
| Human RCTs (obese adults) |
↓ Triglycerides and LDL cholesterol, improved insulin sensitivity
|
| Rodent metabolic models |
↑ Lipolysis and ↓ adipocyte size in abdominal fat depots
|
| In vitro pituitary assays |
↑ GH secretion through cAMP-mediated GHRH receptor activation
|
| Comparative GH study |
Maintains GH pulsatility and avoids receptor desensitization
|
| Muscle regeneration models |
↑ Protein synthesis and satellite cell activation via IGF-1
|
| Neurocognitive research (pilot trials) |
↑ Memory performance and GH-IGF-1-axis normalization
|
Stack Suggestions
Tesamorelin is often combined with CJC-1295 (No-DAC) or Ipamorelin to amplify natural GH release in research settings.
It can also be studied with AOD-9604 or 5-Amino-1MQ for enhanced fat metabolism and body composition optimization.
Stacks discussed are for experimental design only, not for safety or efficacy guidance.
Pen Dosage Chart
| Tesamorelin Pen 10 mg | |
| Volume | 2.0 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 20 clicks = 1 mg |
| Tesamorelin Pen 20 mg | |
| Volume | 2.0 mL |
| mg/mL | 10 mg/mL |
| Click-to-Dose | 1 click = 0.10 mg |
| Example(s) | 10 clicks = 1 mg |
Dosage & Protocols Variations
Standard GH-Releasing Protocol
- Dose: 1 – 2 mg
- Duration: 8 – 12 weeks
- Frequency: 1× daily
- Cycle Interval: 8-week rest
- Goal / Description: Used to stimulate GH and IGF-1 secretion in controlled models
Lipolytic Research Protocol
- Dose: 2 mg
- Duration: 12 – 16 weeks
- Frequency: 1× daily
- Cycle Interval: 8-week rest
- Goal / Description: Focused on visceral fat and lipid metabolism studies
Endocrine Optimization Protocol
- Dose: 1 mg
- Duration: 8 – 12 weeks
- Frequency: Every Other Day
- Cycle Interval: 4-week rest
- Goal / Description: Investigates hormonal axis modulation and pituitary response
Maintenance Protocol
- Dose: 1 mg
- Duration: ongoing
- Frequency: 2× weekly
- Cycle Interval: 12-week rest
- Goal / Description: Maintains GH/IGF-1 balance in prolonged research conditions
Possible Side Effects
Tesamorelin, as a research peptide, may lead to various side effects in experimental models, though not all subjects experience them. These reactions often relate to its GH-releasing activity, affecting musculoskeletal and metabolic systems. Side effects tend to be more noticeable at initiation or higher doses via subcutaneous injection.
Injection Site Reactions: Redness, swelling, or pain at the administration site, typically resolving quickly.
Arthralgia: Joint pain or stiffness, linked to GH fluctuations.
Headache: Mild to moderate headaches, possibly from IGF-1 changes.
Peripheral Edema: Fluid retention in extremities.
Muscle Pain: Myalgia in some models.
Carpal Tunnel Symptoms: Numbness or tingling, rare but reported.
Hypersensitivity: Allergic reactions like rash.
Increased IGF-1 Related: Potential for glucose intolerance monitoring.
It is crucial to note that most side effects are transient and resolve upon discontinuation. However, monitoring is essential in research protocols to track any persistent issues like malignancy risks, though not directly linked.
Product Attributes
- CAS #: 218949-48-5
- Molecular Formula: C221H366N72O67S
- Sequence (AA): Tyr-DAla-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
- Molecular Weight: 5135.87 g/mol
- PubChem CID: 10492583
- Half-Life: ~30 minutes (biological activity extended up to 2 hours)
- Synonyms: TH9507, Tesamorelin acetate, Egrifta SV WR, hGRF / GHRH / Growth hormone-releasing factor analog
- Type: Synthetic GHRH analog
- Research Focus: Weight Loss, Anti-Age, Endocrine Regulation
Scientific References
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Human RCT
- The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV Human RCT
- Effects of tesamorelin on nonalcoholic fatty liver disease in HIV: a randomized, double-blind, multicenter trial Human RCT
- Tesamorelin improves fat quality independent of changes in fat quantity Human observational
- Tesamorelin, a human growth hormone releasing factor analogue Review
- Growth hormone and tesamorelin in the management of HIV disease Review
- Effects of tesamorelin on neurocognitive impairment in persons with HIV Human RCT
- Tesamorelin improves fat quality independent of changes in fat quantity Human RCT
- Tesamorelin – LiverTox – NCBI Bookshelf Review
- Tesamorelin as an adjunct to exercise for improving physical function and muscle health in older adults with HIV Ongoing study
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™ – precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1 – 7°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6 – 8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS cold-chain transport boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not support merchants in this field.
For this reason, we accept bank transfers only.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day (cut-off dependent).
This method ensures compliance, security, and continuity of service for all customers across the EU.
